Our Commitment to Access
At BeOne Medicines, access is not an aspiration, it is an imperative.
At BeOne Medicines, we are building the world’s leading oncology company to reach more patients than ever before. For us, access isn’t an aspiration, it’s an imperative.
Over the last two decades, cancer outcomes have dramatically improved, but there is still work to be done. Reaching every patient who needs our medicines, regardless of where they live, is central to that work.
From clinical trial enrollment to each stage of the treatment journey, we are building the infrastructure, partnerships, and programs to deliver innovative cancer therapies to more patients around the world, faster, reliably, and at scale. Together, we are how the world stops cancer.
Global Access Through Research & Development
Access to innovative cancer therapies starts with global research. Our fully integrated in-house model connects research, translational science, and clinical execution, with patient perspectives woven into every stage — from early research decisions to trial design — creating medicines that are innovative, impactful, and built to reach the patients who need them most. Having a clinical trial footprint that is distributed around the world helps us accelerate the process from discovery to delivery.
- Access starts with a pipeline built for impact, advancing more than 40+ assets targeting the high-burden cancers affecting the most patients worldwide.
- Patient insights shape our research at every stage through councils, advisory boards, and direct collaboration.
- Our integrated in-house model is a strategic advantage, giving us direct control over quality, speed, and scale —helping patients gain access to breakthrough treatments faster.
We advance research with communities to ensure clinical trials reflect real-world patients. Our partnerships aim to reduce participation barriers, expand access to innovation, and strengthen the rigor and relevance of our clinical evidence.
And we’re doing this at scale:
*as of the end of 2025
Global Access Through Manufacturing
Across our global manufacturing network, we continue to advance our productivity and capabilities to support the unique demands of cancer medicine production. By internalizing our manufacturing process and reducing our reliance on third parties, we can act quickly when breakthroughs emerge, maintain tight quality control for complex biologics and antibody-drug conjugates (ADCs), and respond with the speed cancer patients need when every day counts.
- Our integrated internal manufacturing capabilities operate under Good Manufacturing Practices (GMP) standards set by regulators worldwide, including the U.S. FDA, European Medicines Agency, China NMPA, Brazil ANVISA, Australia TGA, and Korea MFDS.
- We are diversifying our active pharmaceutical ingredient (API) supply to reduce single-source dependency and strengthen long-term supply resilience for patients worldwide.
- Each of our global manufacturing sites is purpose-built to support the unique demands of cancer medicine production. By owning and controlling our manufacturing process rather than relying on contract manufacturers, we can scale rapidly when a breakthrough emerges, maintain tight quality control for complex biologics and ADCs, and respond with the speed cancer patients need when every day counts.
- Reliable access requires more than global manufacturing. We are building localized logistics networks and regional packaging and distribution hubs that bring our cancer therapies closer to patients, ensuring reliable, uninterrupted supply in every market we serve.
Global Access Through Local Pathways
Every cancer patient is unique, and so is every market we serve. Recognizing this complexity, we collaborate with health systems and access stakeholders worldwide to accelerate timelines and support broad patient access. Through thoughtful engagement with regulatory and reimbursement authorities, patient support programs, and early and alternative access pathways, we work to ensure that approvals translate into real-world treatment options for patients who need them around the world.
We’re working with health systems and access stakeholders worldwide to bring breakthrough therapies to patients everywhere.
Our therapies have treated over 2.5 million patients since commercialization.
We know that approval does not always equal access. We work closely with reimbursement authorities around the world to help patients access our medicines as quickly and broadly as possible.
Where it helps patients, we also work with local and regional organizations to navigate market-specific access pathways and expand availability. For example, we have reached:
Our myBeOneSupport program in the U.S. and Canada provides personalized assistance from dedicated Oncology Nurse Advocates to help with financial assistance, treatment education, and care coordination.
Global Access Through Community Collaboration
Cancer is too complex to solve alone. That’s why we collaborate with patient communities and advocates to strengthen the real-world support beyond treatment — education, diagnosis, and connections to care — especially where traditional access pathways fall short.
patient advocacy organization partnerships we’ve built worldwide focused on education, earlier diagnosis, clinical trial awareness, and reducing barriers to care
- We co-develop and support community-based programs that help patients move from awareness to action, such as connecting people to screening, guiding them through referrals, and helping them navigate the next steps to care.
- Together, we build programs that meet patients where they are — improving health literacy, supporting navigation to appropriate care, and expanding participation in research.
- These initiatives are about more than driving awareness — they’re interventions designed to improve outcomes.
- Our global and regional patient advocacy councils enable bi-directional insight sharing, embedding the patient voice across the full continuum—from early research through development and across the product lifecycle.
Global Access Through Philanthropy
The BeOne Care Foundation is dedicated to eliminating barriers in access to cancer care and helping foster accessible cancer care in underrepresented communities around the world.
in Access to Cancer Care grants supporting cancer screening, detection, and diagnostic capabilities in underserved and high-risk communities worldwide.
In 2025, our grants helped support:
- Frankly Speaking About Cancer, a cancer screening and support program from Cancer Support Community, a Washington, D.C.-based organization that helps people impacted by cancer navigate barriers to care, reached approximately 338,000 people in the U.S.
- February Orange, a leukemia awareness and education campaign from ABRALE, a São Paulo-based organization dedicated to ensuring all people with blood cancer in Brazil access the best treatment, impacted over 200,000 people and supported 396 patients.
- Leukemia is Not All the Same, an online awareness campaign from Instituto Camaleão, a Porto Alegre-based organization that supports cancer patients through recovery and reintegration, reached over 2.4 million people and trained 62 health professionals and students.
- In partnership with the Max Foundation and BeOne, we’re delivering medicine at no cost to patients with chronic lymphocytic treatment across low- and middle-income countries, reaching more than 300 patients in Armenia, Ethiopia, and Nepal during the first three years of our partnership.